Top

Irish Journal of Medical Science (1971 -)

03-04-2024 | Gentamicin | Original Article

Paediatric Escherichia coli urinary tract infection: susceptibility trends and clinical management—a retrospective analysis of a 10-year period

Authors: Seán Olann Whelan, Sarah Kyne, Andrew Dore, Mark Glynn, Frances Higgins, Belinda Hanahoe, Frank Moriarty, Edina Moylett, Martin Cormican

Published in: Irish Journal of Medical Science (1971 -)

Abstract

Background

Escherichia coli is the predominant urinary pathogen in children. Irish and international studies have demonstrated increasing antimicrobial resistance (AMR) to antibiotics such as co-amoxiclav.

Aims

We aimed to (1) examine the AMR patterns of paediatric urinary E. coli isolates, from both hospital and community sources, over a 10-year period; (2) assess the effectiveness of Children’s Health Ireland (CHI) antimicrobial guidance given local susceptibility data; and (3) review the clinical management of an admitted patient sub-set over a 6-year period.

Methods

Pure growth of urinary E. coli from patients aged ≤ 14 from 2012 to 2021 were analysed for AMR. Differences in susceptibility rates were assessed. A retrospective chart review conducted on inpatients aged ≥ 2 months to ≤ 14 years, 2016–2021.

Results

E. coli accounted for 70.8% of likely significant positive pure growth cultures (9314 isolates). Susceptibility to co-amoxiclav significantly increased over time, from 66.7% to 80.4% (2016–2021, p < 0.001). Nitrofurantoin and cefalexin had significantly higher susceptibility rates than trimethoprim (< 70% annually). 85.1% of isolates were susceptible to the combination of co-amoxiclav and gentamicin, recommended for those > 2months and systemically unwell. The additional gain in empiric susceptibility provided by gentamicin above that provided by co-amoxiclav alone has fallen from 16.4% to 6.7% (2016–2021). The 222 clinical cases reviewed showed improved antimicrobial guideline compliance over time.

Conclusions

This study provides important regional AMR data. Co-amoxiclav susceptibility increased significantly over time, contrasting with previous studies. This was temporally associated with stewardship measures reducing co-amoxiclav prescribing. Decreasing utility of gentamicin supports recent CHI guideline updates reducing gentamicin use.

Available only for authorised users

Coulthard MG, Lambert HJ, Keir MJ (1997) Occurrence of renal scars in children after their first referral for urinary tract infection. BMJ 315:918–919. https://doi.org/10.1136/bmj.315.7113.918CrossRefPubMedPubMedCentral

Shaw KN, Gorelick M, McGowan KL et al (1998) Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics 102:e16. https://doi.org/10.1542/peds.102.2.e16CrossRefPubMed

Hoberman A, Chao HP, Keller DM et al (1993) Prevalence of urinary tract infection in febrile infants. J Pediatr 123:17–23. https://doi.org/10.1016/s0022-3476(05)81531-8CrossRefPubMed

O’Brien K, Edwards A, Hood K, Butler CC (2013) Prevalence of urinary tract infection in acutely unwell children in general practice: a prospective study with systematic urine sampling. Br J Gen Pract 63:e156–e164. https://doi.org/10.3399/bjgp13X663127CrossRefPubMedPubMedCentral

Shaikh N, Morone NE, Bost JE, Farrell MH (2008) Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 27:302–308. https://doi.org/10.1097/INF.0b013e31815e4122CrossRefPubMed

Gondim R, Azevedo R, Braga AANM et al (2018) Risk factors for urinary tract infection in children with urinary urgency. Int Braz J Urol 44:378–383. https://doi.org/10.1590/S1677-5538.IBJU.2017.0434CrossRefPubMedPubMedCentral

Newman TB, Bernzweig JA, Takayama JI et al (2002) Urine testing and urinary tract infections in febrile infants seen in office settings: the pediatric research in office settings’ febrile infant study. Arch Pediatr Adolesc Med 156:44–54. https://doi.org/10.1001/archpedi.156.1.44CrossRefPubMed

Gaspari RJ, Dickson E, Karlowsky J, Doern G (2005) Antibiotic resistance trends in paediatric uropathogens. Int J Antimicrob Agents 26:267–271. https://doi.org/10.1016/j.ijantimicag.2005.07.009CrossRefPubMed

Winberg J, Andersen HJ, Bergström T et al (1974) Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr Scand Suppl. https://doi.org/10.1111/j.1651-2227.1974.tb05718.xCrossRefPubMed

10.

Bien J, Sokolova O, Bozko P (2012) Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol 2012:681473. https://doi.org/10.1155/2012/681473CrossRefPubMedPubMedCentral

11.

Terlizzi ME, Gribaudo G, Maffei ME (2017) UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol 8:1566. https://doi.org/10.3389/fmicb.2017.01566CrossRefPubMedPubMedCentral

12.

Orellana P, Baquedano P, Rangarajan V et al (2004) Relationship between acute pyelonephritis, renal scarring, and vesicoureteral reflux. Results of a coordinated research project. Pediatr Nephrol 19:1122–1126. https://doi.org/10.1007/s00467-004-1501-5CrossRefPubMed

13.

Romandini A, Pani A, Schenardi PA et al (2021) Antibiotic Resistance in Pediatric Infections: Global Emerging Threats. Predicting the Near Future Antibiotics (Basel). https://doi.org/10.3390/antibiotics10040393CrossRefPubMedPubMedCentral

14.

Bryce A, Hay AD, Lane IF et al (2016) Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. https://doi.org/10.1136/bmj.i939CrossRefPubMedPubMedCentral

15.

Nicolle L, Anderson PAM, Conly J et al (2006) Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physician 52:612–618PubMedPubMedCentral

16.

Kariv G, Paul M, Shani V et al (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19:629–633. https://doi.org/10.1111/j.1469-0691.2012.03965.xCrossRefPubMed

17.

SARI Hospital Antimicrobial Stewardship Working Group (2009) Guidelines for antimicrobial stewardship in hospitals in Ireland. Health Protection Surveillance Centre, Dublin

18.

Pyelonephritis (acute): antimicrobial prescribing (2018) NICE Guideline NG111. Last update September 2019. https://www.nice.org.uk/guidance/ng111

19.

Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (2015) NICE Guideline NG15. Last update January 2018. https://www.nice.org.uk/guidance/ng15

20.

Chulain MN, Murray A-M, Corbett-Feeney G, Cormican M (2005) Antimicrobial resistance in E. coli associated with urinary tract infection in the west of Ireland. Ir J Med Sci 174:6–9. https://doi.org/10.1007/BF03168974CrossRefPubMed

21.

O’Grady MC, Barry L, Corcoran GD et al (2019) Empirical treatment of urinary tract infections: how rational are our guidelines? J Antimicrob Chemother 74:214–217. https://doi.org/10.1093/jac/dky405CrossRefPubMed

22.

Stapleton PJ, Lundon DJ, McWade R et al (2017) Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. Ir J Med Sci 186:733–741. https://doi.org/10.1007/s11845-016-1538-zCrossRefPubMed

23.

Cullen IM, Manecksha RP, McCullagh E et al (2012) The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999–2009. BJU Int 109:1198–1206. https://doi.org/10.1111/j.1464-410X.2011.10528.xCrossRefPubMed

24.

Trayer J, Maka Z, O’keeffe A et al (2021) Trends in antimicrobial resistance in children admitted with Escherichia coli urinary tract infections. Ir Med J 114:284

25.

Departments of Pharmacy, Infectious Diseases and Microbiology, CHI at Crumlin, Temple Street and Tallaght Children’s Health Ireland Antmicrobial Guidelines 2021. In: 2021. https://www.olchc.ie/healthcare-professionals/clinical-guidelines/antimicrobial-guidelines-2021.pdf. 29 Mar 2022

26.

Health Service Executive (2020) UTI in children. In: Antibiotic Prescribing Guidelines for Treatment of Community Infections. https://www.hse.ie/eng/services/list/2/gp/antibiotic-prescribing/conditions-and-treatments/urinary/uti-in-children/. 29 Mar 2022

27.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) EUCAST Disk Diffusion Test Methodology. https://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/. 12 Apr 2022

28.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2021) The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 11.0, 2021. http://www.eucast.org/clinical_breakpoints/

29.

Clinical & Laboratory Standards Institute:CLSI (2018) M02: Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th Edition. https://clsi.org/standards/products/microbiology/documents/m02/

30.

Chen H-E, Tain Y-L, Kuo H-C, Hsu C-N (2020) Trends in antimicrobial susceptibility of Escherichia coli isolates in a Taiwanese child cohort with urinary tract infections between 2004 and 2018. Antibiotics (Basel). https://doi.org/10.3390/antibiotics9080501CrossRefPubMedPubMedCentral

31.

Cag Y, Haciseyitoglu D, Ozdemir AA, Cag Y (2021) Antibiotic resistance and bacteria in urinary tract infections in pediatric patients. Medeni Med J 36:217–224. https://doi.org/10.5222/MMJ.2021.78535CrossRefPubMedPubMedCentral

32.

Department of Health (2017) Ireland’s national action plan on antimicrobial resistance 2017–2020. (iNAP). http://health.gov.ie/national-patient-safety-office/patient-safety-surveillance/antimicrobialresistance-%0Damr/

33.

Public Health Agency of Sweden NVI (2015) Consumption of antibiotics and occurrence of antibiotic resistance in Sweden. Swedres-Svarm 2014

34.

Public Health England (2014) English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2014

35.

Health Service Executive – Antibioticprescribing.ie (2014) UTI in Children https://www.hse.ie/eng/services/list/2/gp/antibiotic-prescribing/conditions-and-treatments/urinary/uti-in-children/. 10 Jan 2024

36.

Health Service Executive - Antibiotic prescribing (2022) Green Red antibiotic QI initiative for community prescribers. https://www.hse.ie/eng/services/list/2/gp/antibiotic-prescribing/antibicrobial-stewardship-audit-tools/campaign-materials/. 3 Apr 2022

37.

Health Service Executive (HSE) (2020) Primary Care Reimbursement Scheme (PCRS) top 100 prescribed products. https://www.sspcrs.ie/portal/annual-reporting/report/pharmacy

38.

Mattsson M, Hong JA, Frazer JS et al (2024) Trends in medication use at the onset of and during the COVID-19 pandemic in the Republic of Ireland: an interrupted time series study. Basic Clin Pharmacol Toxicol 134:231–240. https://doi.org/10.1111/BCPT.13958CrossRefPubMed

39.

Seppälä H, Klaukka T, Vuopio-Varkila J et al (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 337:441–446. https://doi.org/10.1056/NEJM199708143370701CrossRefPubMed

40.

Schuts EC, Hulscher MEJL, Mouton JW et al (2016) Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 16:847–856. https://doi.org/10.1016/S1473-3099(16)00065-7CrossRefPubMed

41.

Di Pietro P, Della Casa Alberighi O, Silvestri M et al (2017) Monitoring adherence to guidelines of antibiotic use in pediatric pneumonia: the MAREA study. Ital J Pediatr 43:113. https://doi.org/10.1186/s13052-017-0432-2CrossRefPubMedPubMedCentral

42.

Wathne JS, Harthug S, Kleppe LKS et al (2019) The association between adherence to national antibiotic guidelines and mortality, readmission and length of stay in hospital inpatients: results from a Norwegian multicentre, observational cohort study. Antimicrob Resist Infect Control 8:63. https://doi.org/10.1186/s13756-019-0515-5CrossRefPubMedPubMedCentral

43.

Spoorenberg V, Hulscher MEJL, Akkermans RP et al (2014) Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis 58:164–169. https://doi.org/10.1093/cid/cit688CrossRefPubMed

44.

van der Velden LBJ, Tromp M, Bleeker-Rovers CP et al (2012) Non-adherence to antimicrobial treatment guidelines results in more broad-spectrum but not more appropriate therapy. Eur J Clin Microbiol Infect Dis 31:1561–1568. https://doi.org/10.1007/s10096-011-1478-5CrossRefPubMed

45.

Nguyen-Ha P-T, Howrie D, Crowley K et al (2016) A quality assessment of a collaborative model of a pediatric antimicrobial stewardship program. Pediatrics. https://doi.org/10.1542/peds.2015-0316CrossRefPubMed

46.

Elias C, Moja L, Mertz D et al (2017) Guideline recommendations and antimicrobial resistance: the need for a change. BMJ Open 7:e016264. https://doi.org/10.1136/bmjopen-2017-016264CrossRefPubMedPubMedCentral

47.

Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120. https://doi.org/10.1093/cid/ciq257CrossRefPubMed

48.

Gupta K (2003) Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 17:243–259. https://doi.org/10.1016/s0891-5520(03)00006-0CrossRefPubMed

49.

Raz R, Chazan B, Kennes Y et al (2002) Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 34:1165–1169. https://doi.org/10.1086/339812CrossRefPubMed

50.

Le TP, Miller LG (2001) Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis 33:615–621. https://doi.org/10.1086/322603CrossRefPubMed

51.

McMullan BJ, Andresen D, Blyth CC et al (2016) Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis 16:e139–e152. https://doi.org/10.1016/S1473-3099(16)30024-XCrossRefPubMed

52.

Strohmeier Y, Hodson EM, Willis NS et al (2014) Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev CD. https://doi.org/10.1002/14651858.CD003772.pub4CrossRef

53.

Newham R, Thomson AH, Semple Y et al (2015) Barriers to the safe and effective use of intravenous gentamicin and vancomycin in Scottish hospitals, and strategies for quality improvement. Eur J Hosp Pharm 22:32–37. https://doi.org/10.1136/EJHPHARM-2014-000483CrossRef

54.

Diepstraten FA, Hoetink AE, Van Grotel M et al (2021) Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. https://doi.org/10.1093/JACAMR/DLAB184CrossRefPubMedPubMedCentral

55.

McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M (2017) Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol 32:2015–2025. https://doi.org/10.1007/S00467-016-3533-Z/TABLES/3CrossRefPubMed

56.

Departments of Pharmacy ID and Microbiology, Children’s Health Ireland (2023) Guidance by infection type: Urinary tract infection. Children’s Health Ireland Antimicrobial Guidelines

57.

Fox MT, Amoah J, Hsu AJ et al (2020) Comparative Effectiveness of Antibiotic Treatment Duration in Children With Pyelonephritis. JAMA Netw Open 3:e203951–e203951. https://doi.org/10.1001/JAMANETWORKOPEN.2020.3951CrossRefPubMedPubMedCentral

58.

Buonsenso D, Sodero G, Mariani F et al (2022) Comparison between short therapy and standard therapy in pediatric patients hospitalized with urinary tract infection: a single center retrospective analysis. Children (Basel). https://doi.org/10.3390/CHILDREN9111647CrossRefPubMed

59.

Sethi N, Carlsen ELM, Schmidt IM et al (2023) Individualised versus standard duration of antibiotic therapy in children with acute uncomplicated febrile urinary tract infection: a study protocol and statistical analysis plan for a multicentre randomised clinical trial. BMJ Open. https://doi.org/10.1136/BMJOPEN-2022-070888CrossRefPubMedPubMedCentral

60.

Eliakim-Raz N, Yahav D, Paul M, Leibovici L (2013) Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection– 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 68:2183–2191. https://doi.org/10.1093/JAC/DKT177CrossRefPubMed

61.

Montini G, Toffolo A, Zucchetta P et al (2007) Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 335:386–388. https://doi.org/10.1136/BMJ.39244.692442.55CrossRefPubMedPubMedCentral

62.

Neuhaus TJ, Berger C, Buechner K et al (2008) Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. Eur J Pediatr 167:1037–1047. https://doi.org/10.1007/S00431-007-0638-1CrossRefPubMed

63.

Strohmeier Y, Hodson EM, Willis NS et al (2014) Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2014. https://doi.org/10.1002/14651858.CD003772.PUB4CrossRefPubMedPubMedCentral

64.

Poirel L, Madec J-Y, Lupo A et al (2018) Antimicrobial resistance in Escherichia coli. Microbiol Spectr. https://doi.org/10.1128/microbiolspec.ARBA-0026-2017CrossRefPubMed

Title: Paediatric Escherichia coli urinary tract infection: susceptibility trends and clinical management—a retrospective analysis of a 10-year period
Authors: Seán Olann Whelan
Sarah Kyne
Andrew Dore
Mark Glynn
Frances Higgins
Belinda Hanahoe
Frank Moriarty
Edina Moylett
Martin Cormican
Publication date: 03-04-2024
Publisher: Springer International Publishing
Keywords: Gentamicin
Urinary Tract Infection
Nitrofurantoin
Cephalexin
Escherichia Coli
Published in: Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-024-03670-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com